Product Program year 2019 Source: CMS Open Payments

Aubagio

Drug Multiple Sclerosis

NDC 58468-0210-1

Open in the dashboard

General payments

$7,425,901

20,297 payments

Research payments

$517,487

100 payments

Through program year 2019, $7,425,901 in general payments and $517,487 in research payments were reported against Aubagio (Multiple Sclerosis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $7,425,901 20,297
2019 Research $517,487 100

Breakdown

Who paid General payments · program year 2019
  1. Genzyme Corporation $7,013,912 20,112 payments
  2. Sanofi-Aventis U.S. LLC $411,589 183 payments
  3. Sanofi US Services Inc. $400 2 payments
Top recipients General payments · program year 2019
  1. Bhupendra Khatri Neurology · Milwaukee, WI $145,328 2% · 77 payments
  2. Mark Cascione Neurology · Tampa, FL $118,370 2% · 106 payments
  3. Annette Howard Neurology · Houston, TX $109,759 1% · 128 payments
  4. Jill Conway Neurology · Charlotte, NC $102,481 1% · 94 payments
  5. Patricia Coyle Neurology · East Setauket, NY $90,051 1% · 31 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Neurology Psychiatry & Neurology $6,797,244 96% · 2,894 practitioners
  2. Clinical Neurophysiology Psychiatry & Neurology $73,863 1% · 50 practitioners
  3. Internal Medicine $67,908 <1% · 50 practitioners
  4. Psychiatry Psychiatry & Neurology $38,665 <1% · 13 practitioners
  5. Neuromuscular Medicine Psychiatry & Neurology $23,029 <1% · 14 practitioners

The top 5 of 74 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Florida $635,465 9% · 319 recipients
  2. California $606,895 8% · 250 recipients
  3. Texas $517,295 7% · 317 recipients
  4. New York $491,509 7% · 229 recipients
  5. Michigan $433,578 6% · 159 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

9,680

Prescriptions dispensed, refills included

Drug cost

$96,646,420

Paid at the pharmacy, in all

Prescribers

479

With 11 or more claims of it

Medicare Part D drugs matched to AUBAGIO, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Aubagio Teriflunomide Same name 479 9,680 $96,646,420

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Angel Chinea Neurology PR 209 $1,944,134 None on record
Anna Baker Physician Assistant WI 144 $1,371,003 $230
Donald Negroski Neurology FL 104 $966,223 None on record
Mary Ann Picone Neurology NJ 91 $931,566 None on record
Sharon Lynch Neurology KS 87 $770,343 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
20,297 general · 100 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record